Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $8.24 Consensus Target Price from Analysts

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $8.37.

A number of brokerages recently weighed in on ZNTL. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Wedbush reaffirmed a "neutral" rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th.

Zentalis Pharmaceuticals Trading Down 4.7%

Shares of ZNTL stock traded down $0.07 during trading on Tuesday, hitting $1.32. The company's stock had a trading volume of 924,533 shares, compared to its average volume of 1,486,582. The company has a market cap of $94.61 million, a PE ratio of -0.42 and a beta of 1.61. The business has a fifty day moving average of $1.34 and a 200-day moving average of $1.98. Zentalis Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $5.70.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, hitting the consensus estimate of ($0.67). As a group, research analysts predict that Zentalis Pharmaceuticals will post -2.42 EPS for the current year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers bought 21,000 shares of the business's stock in a transaction on Wednesday, April 30th. The stock was purchased at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the completion of the transaction, the director now directly owns 281,192 shares of the company's stock, valued at $393,668.80. This trade represents a 8.07% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.90% of the company's stock.

Institutional Trading of Zentalis Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Corton Capital Inc. bought a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $32,000. Captrust Financial Advisors bought a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter valued at $33,000. Cerity Partners LLC lifted its holdings in Zentalis Pharmaceuticals by 58.7% during the 1st quarter. Cerity Partners LLC now owns 20,501 shares of the company's stock worth $33,000 after purchasing an additional 7,579 shares in the last quarter. Prudential Financial Inc. purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter worth about $39,000. Finally, Vident Advisory LLC bought a new position in Zentalis Pharmaceuticals in the 4th quarter worth about $45,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.